Secarna Pharmaceuticals GmbH & Co. KG | WebDisclosure

Basculer en Français

9821	Companies
197095	Keywords
128173	Articles
104823	Press releases

Headlines Articles Press releases Secarna Pharmaceuticals GmbH & Co. KG

Home
Companies
Secarna Pharmaceuticals GmbH & Co. KG

PRESS RELEASE

published on 03/26/2025 at 14:00, 10 months 13 days ago

Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 as monotherapy and in combination with immune checkpoint inhibitors at AACR
Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 at AACR, showcasing potential to enhance immune checkpoint inhibitors' efficacy

Secarna Pharmaceuticals AACR Antisense Oligonucleotide SECN-15 NRP1
BRIEF

published on 10/31/2024 at 16:08, 1 year 3 months ago

Secarna Pharmaceuticals nomme son nouveau PDG, Konstantin Petropoulos

Nomination Du PDG Produits Biopharmaceutiques Secarna Pharmaceutique Constantin Petropoulos Thérapeutique Par Oligonucléotides
BRIEF

published on 10/31/2024 at 16:08, 1 year 3 months ago

Secarna Pharmaceuticals Appoints New CEO Konstantin Petropoulos

CEO Appointment Biopharmaceuticals Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
PRESS RELEASE

published on 10/31/2024 at 16:03, 1 year 3 months ago

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Office
Secarna Pharmaceuticals announces Konstantin Petropoulos as new CEO, succeeding Alexander Gebauer, focusing on oligonucleotide therapeutics. Petropoulos brings extensive industry experience

Business Development CEO Appointment Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
BRIEF

published on 09/09/2024 at 14:05, 1 year 4 months ago

Secarna Pharmaceuticals présentera le potentiel de l'ASO lors du sommet sur les thérapies contre les inflammasomes

Secarna Pharmaceutique Inflammation NLRP3 Les OSA Sommet Sur Les Thérapies À Base D'inflammasome
BRIEF

published on 09/09/2024 at 14:05, 1 year 4 months ago

Secarna Pharmaceuticals to Showcase ASO Potential at Inflammasome Therapeutics Summit

Secarna Pharmaceuticals ASOs Inflammation NLRP3 Inflammasome Therapeutics Summit
PRESS RELEASE

published on 09/09/2024 at 14:00, 1 year 4 months ago

Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
Secarna Pharmaceuticals presents ASO data targeting NLRP3 at Inflammasome Therapeutics Summit, showcasing potential in inflammatory disease treatment

Secarna Pharmaceuticals ASOs NLRP3 Inflammasome Summit Inflammatory Disease
BRIEF

published on 09/04/2024 at 14:05, 1 year 5 months ago

Secarna crée un comité consultatif en oncologie composé des experts Prof. Dr. Eggermont et Prof. Dr. Zippelius

Secarna Pharmaceutique Conseil Consultatif Scientifique SECN-15 Experts En Oncologie Neuropiline 1
BRIEF

published on 09/04/2024 at 14:05, 1 year 5 months ago

Secarna Establishes Oncology Advisory Board with Experts Prof. Dr. Eggermont and Prof. Dr. Zippelius

Scientific Advisory Board Secarna Pharmaceuticals Oncology Experts SECN-15 Neuropilin 1
PRESS RELEASE

published on 09/04/2024 at 14:00, 1 year 5 months ago

Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
Secarna Pharmaceuticals GmbH & Co. KG establishes an oncology Scientific Advisory Board with leading experts Prof. Dr. Eggermont and Prof. Dr. Zippelius to guide the development of SECN-15 and the oncology pipeline

Scientific Advisory Board Oncology Therapeutics Secarna Pharmaceuticals SECN-15

Accesswire

Published on 02/08/2026 at 21:00, 8 hours 31 minutes ago

Banyan Gold Extends Airstrip and High-Grade Mineralization to 350m Vertical Depth, Yukon, Canada
Published on 02/07/2026 at 01:00, 2 days 4 hours ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 2 days 6 hours ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 2 days 7 hours ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 2 days 14 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 21:00, 1 day 8 hours ago

Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 1 day 12 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 1 day 13 hours ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 2 days 10 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 2 days 11 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG

Les Echos

Published on 02/06/2026 at 18:22, 2 days 11 hours ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 2 days 11 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 2 days 13 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 2 days 13 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 2 days 21 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE